A 
Abbott Laboratories ABT · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
110.51
+0.53%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$44.33bn
FY2016FY2025
Net income
$6.52bn
FY2016FY2025
Free cash flow
$7.39bn
FY2016FY2025
Shareholders' equity
$52.13bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.33bn | $41.95bn | $40.11bn | $43.65bn | $43.08bn | $34.61bn | $31.90bn | $30.58bn | $27.39bn | $20.85bn |
| Gross profit | $24.61bn | $21.32bn | $20.04bn | $22.32bn | $23.21bn | $17.38bn | $16.69bn | $15.82bn | $13.07bn | $11.24bn |
| Research and development | $2.96bn | $2.82bn | $2.72bn | $2.85bn | $2.74bn | $2.42bn | $2.41bn | $2.29bn | $2.13bn | $1.36bn |
| Operating income | $8.23bn | $7.04bn | $6.68bn | $8.36bn | $9.20bn | $5.29bn | $4.59bn | $3.84bn | $2.75bn | $3.25bn |
| Net income | $6.52bn | $13.40bn | $5.72bn | $6.93bn | $7.07bn | $4.50bn | $3.69bn | $2.37bn | $477.0m | $1.40bn |
| Diluted earnings per share | 3.73 | 7.68 | 3.27 | 3.95 | 3.97 | 2.51 | 2.07 | 1.33 | 0.27 | 0.94 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $86.71bn | $81.41bn | $73.21bn | $74.44bn | $75.20bn | $72.55bn | $67.89bn | $67.17bn | $76.25bn | $55.01bn |
| Cash and short-term investments | $8.94bn | $7.97bn | $7.28bn | $10.17bn | $10.25bn | $7.15bn | $4.14bn | $4.09bn | $9.61bn | $18.77bn |
| Total liabilities | $33.94bn | $33.51bn | $34.39bn | $37.53bn | $39.17bn | $39.55bn | $36.59bn | $36.45bn | $45.15bn | $31.95bn |
| Debt | $12.93bn | $14.13bn | $14.68bn | $16.77bn | $18.05bn | $18.75bn | $17.59bn | $19.57bn | $27.92bn | $21.55bn |
| Shareholders' equity | $52.13bn | $47.66bn | $38.60bn | $36.69bn | $35.80bn | $32.78bn | $31.09bn | $30.52bn | $30.90bn | $20.54bn |
| Shares outstanding | 1,747m | 1,746m | 1,748m | 1,754m | 1,782m | 1,789m | 1,781m | 1,774m | 1,746m | 1,483m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $9.57bn | $8.56bn | $7.26bn | $9.58bn | $10.53bn | $7.90bn | $6.14bn | $6.30bn | $5.57bn | $3.20bn |
| Capital spending | −$2.17bn | −$2.21bn | −$2.20bn | −$1.78bn | −$1.89bn | −$2.18bn | −$1.64bn | −$1.39bn | −$1.14bn | −$1.12bn |
| Free cash flow | $7.39bn | $6.35bn | $5.06bn | $7.80bn | $8.65bn | $5.72bn | $4.50bn | $4.91bn | $4.43bn | $2.08bn |
| Dividends paid | −$4.12bn | −$3.84bn | −$3.56bn | −$3.31bn | −$3.20bn | −$2.56bn | −$2.27bn | −$1.97bn | −$1.85bn | −$1.54bn |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.59bn | $11.16bn | $11.46bn | $11.37bn | $11.14bn | $10.36bn | $10.97bn | $10.63bn |
| Gross profit | $7.30bn | $6.28bn | $6.54bn | $6.34bn | $6.29bn | $5.44bn | $5.60bn | $5.43bn |
| Operating income | $1.78bn | $1.84bn | $2.29bn | $2.10bn | $2.10bn | $1.74bn | $2.04bn | $1.87bn |
| Net income | $928.0m | $1.08bn | $1.78bn | $1.64bn | $1.78bn | $1.32bn | $9.23bn | $1.65bn |
| Diluted earnings per share | 0.53 | 0.62 | 1.02 | 0.94 | 1.02 | 0.76 | 5.29 | 0.94 |
| Cash from operations | — | $1.31bn | $3.31bn | $2.79bn | $2.05bn | $1.42bn | $2.87bn | $2.71bn |
| Capital spending | — | −$399.0m | −$689.0m | −$496.0m | −$502.0m | −$484.0m | −$720.0m | −$556.0m |
| Free cash flow | — | $916.0m | $2.63bn | $2.29bn | $1.54bn | $933.0m | $2.15bn | $2.15bn |
| Total assets | — | $110.43bn | $86.71bn | $84.18bn | $84.00bn | $81.45bn | $81.41bn | $74.36bn |
| Cash and short-term investments | — | $7.29bn | $8.94bn | $7.73bn | $7.28bn | $6.84bn | $7.97bn | $7.79bn |
| Debt | — | $34.05bn | $13.21bn | $12.94bn | $13.44bn | $13.24bn | $14.38bn | $14.98bn |
| Shareholders' equity | — | $52.06bn | $52.13bn | $50.95bn | $50.56bn | $48.81bn | $47.66bn | $39.80bn |
Financial ratios
Data as of 5 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 55.5% | 50.8% | 50.0% | 51.1% | 53.9% | 50.2% |
| Operating margin | 18.6% | 16.8% | 16.7% | 19.2% | 21.4% | 15.3% |
| Net margin | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% |
| Return on equity | 12.5% | 28.1% | 14.8% | 18.9% | 19.8% | 13.7% |
| Return on assets | 7.5% | 16.5% | 7.8% | 9.3% | 9.4% | 6.2% |
| Free cash flow yield | 6.2% | 5.7% | 5.0% | 6.0% | 6.4% | 5.2% |
| Revenue growth | 5.7% | 4.6% | -8.1% | 1.3% | 24.5% | 8.5% |
| Earnings growth | -51.3% | 134.2% | -17.5% | -2.0% | 57.3% | 21.9% |
| Current ratio | 1.58x | 1.67x | 1.64x | 1.63x | 1.85x | 1.72x |
| Debt to equity | 0.25x | 0.30x | 0.39x | 0.46x | 0.51x | 0.58x |
| Equity ratio | 60.1% | 58.5% | 52.7% | 49.3% | 47.6% | 45.2% |
| Interest coverage | 24.14x | 11.67x | 9.57x | 26.55x | 22.44x | 7.47x |
| R&D as a share of sales | 6.7% | 6.7% | 6.8% | 6.5% | 6.4% | 7.0% |
| Buybacks as a share of market value | -0.1% | 0.1% | 0.3% | 1.6% | 0.4% | -0.4% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 0.5% | 5.1% | 8.1% |
| Operating income | -0.5% | 9.2% | 10.8% |
| Net income | -2.0% | 7.7% | 4.0% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 53.2% | 51.9% | 52.0% | 51.9% |
| Operating margin | 17.7% | 17.8% | 18.1% | 16.4% |
| Net margin | 23.1% | 19.2% | 17.8% | 14.9% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 33.5 | 14.7 | 33.6 | 27.8 | 35.5 | 43.6 | 42.0 | 54.2 | 208.9 | 40.7 |
| Price to sales | 4.9 | 4.7 | 4.8 | 4.4 | 5.8 | 5.7 | 4.8 | 4.2 | 3.6 | 2.7 |
Market value over time
29 Apr 2016 to 4 Sept 2026, in USD
$57.73bn$188.82bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | 12% | 3% | 2% | -21% | 25% | 25% | 27% | 20% | 49% | -11% |
Dividends and splits
Per share, in the currency the company pays
Paid for 52 years. Last went ex-dividend on 15 Oct 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 1.89 | 2.40 | 2.24 | 2.08 | 1.92 | 1.82 | 1.53 | 1.64 |
- 2-for-1 split · 1 Jun 1998
- 2-for-1 split · 1 Jun 1992
- 2-for-1 split · 1 Jun 1990
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.